References of "Martin, Didier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEarly termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.
Robe, Pierre ULg; Martin, Didier ULg; Nguyen-Khac, Minh-Tuan ULg et al

in BMC Cancer (2009), 9

BACKGROUND: Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas. As it presents an ... [more ▼]

BACKGROUND: Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas. As it presents an excellent safety profile, we initiated a phase 1/2 clinical study of this anti-inflammatory drug for the treatment of recurrent WHO grade 3 and 4 astrocytic gliomas in adults. METHODS: 10 patients with advanced recurrent anaplastic astrocytoma (n = 2) or glioblastoma (n = 8) aged 32-62 years were recruited prior to the planned interim analysis of the study. Subjects were randomly assigned to daily doses of 1.5, 3, 4.5, or 6 grams of oral sulfasalazine, and treated until clinical or radiological evidence of disease progression or the development of serious or unbearable side effects. Primary endpoints were the evaluation of toxicities according to the CTCAE v.3.0, and the observation of radiological tumor responses based on MacDonald criteria. RESULTS: No clinical response was observed. One tumor remained stable for 2 months with sulfasalazine treatment, at the lowest daily dose of the drug. The median progression-free survival was 32 days. Side effects were common, as all patients developed grade 1-3 adverse events (mean: 7.2/patient), four patients developed grade 4 toxicity. Two patients died while on treatment or shortly after its discontinuation. CONCLUSION: Although the proper influence of sulfasalazine treatment on patient outcome was difficult to ascertain in these debilitated patients with a large tumor burden (median KPS = 50), ISRCTN45828668 was terminated after its interim analysis. This study urges to exert cautiousness in future trials of Sulfasalazine for the treatment of malignant gliomas. TRIAL REGISTRATION: Current Controlled Trials ISRCTN45828668. [less ▲]

Detailed reference viewed: 48 (14 ULg)
Full Text
Peer Reviewed
See detailHypopituitarisme consécutif aux atteintes cérébrales: le traumatisme cranien et l'hémorragie sous-arachnoidienne mis en cause.
Valdes Socin, Hernan Gonzalo ULg; Vroonen, Laurent ULg; Robe, Pierre ULg et al

in Revue Médicale de Liège (2009), 64(9), 457-463

Brain injuries namely traumatic brain injuries (TBI) and subarachnoid haemorrhage (SAH) are relevant causes of acquired adult hypopituitarism, perhaps more prevalent than ever believed. TBI represent a ... [more ▼]

Brain injuries namely traumatic brain injuries (TBI) and subarachnoid haemorrhage (SAH) are relevant causes of acquired adult hypopituitarism, perhaps more prevalent than ever believed. TBI represent a major health problem with an annual incidence of 300 cases per 100.000. SAH affects six new cases per 1.000.000 habitants in USA. In Belgium we estimate nearly 30.000 new TBI cases and 600 SAH cases per year. In the English literature, TBI secondary hypopituitarism has been well documented in 14 retrospective and prospective series accounting for 1.077 cases. In all these series the main pituitary deficits were: GH (14%), ACTH (14%), gonadotrope (18%), TSH (7%) and diabetes insipidus (4%). SAH was documented as a cause of hypopituitarism in three retrospective series accounting for 110 cases and in one prospective series. In all these series main pituitary deficits were GH (25%), ACTH (15%), gonadotrope (8.5%), TSH (6%) and diabetes insipidus (4%). In this review, we analyze recent data and discuss diagnostic and treatment features of secondary hypopituitarism due TBI and SAH. [less ▲]

Detailed reference viewed: 602 (11 ULg)
Peer Reviewed
See detailNon rigid stabilization of the spine.
Martin, Didier ULg

Conference (2008, November 21)

Detailed reference viewed: 2 (1 ULg)
Peer Reviewed
See detailO-ARM Symposium
Martin, Didier ULg

Conference (2008, November 14)

Detailed reference viewed: 31 (2 ULg)
Peer Reviewed
See detailTable ronde : La myélopathie cervicarthrosique.
Martin, Didier ULg

Conference (2008, November 02)

Detailed reference viewed: 25 (1 ULg)
See detailLa hernie discale thoracique
Martin, Didier ULg

Scientific conference (2008, October 29)

Detailed reference viewed: 33 (1 ULg)
Peer Reviewed
See detailL’hémorragie cérébrale : le coup de tonnerre dans un ciel serein
Martin, Didier ULg

Conference (2008, October 23)

Detailed reference viewed: 4 (0 ULg)
Peer Reviewed
See detailNASS Congress
Martin, Didier ULg

Conference (2008, October 14)

Detailed reference viewed: 4 (0 ULg)
See detailIRM interventionnelle : vers une neuronavigation en temps reel
Martin, Didier ULg

Conference (2008, October 11)

Detailed reference viewed: 3 (0 ULg)
See detailPrise en charge médicale et neurochirurgicale de la spasticité
Martin, Didier ULg

Scientific conference (2008, June 04)

Detailed reference viewed: 17 (3 ULg)
See detailLe diagnostic des démences : comment et pourquoi ?
Martin, Didier ULg

Scientific conference (2008, March 19)

Detailed reference viewed: 11 (0 ULg)
Peer Reviewed
See detailPost-Mortem, high resolution (9.4 Tesla) MRI of spinal cord injury in the rat, correlated with histology
Phan Ba, Remy ULg; Scholtes, Félix ULg; Theunissen, E. et al

Conference (2008, March 12)

Detailed reference viewed: 19 (3 ULg)
See detailMedical imaging
Martin, Didier ULg

Conference (2008, March 12)

Detailed reference viewed: 9 (2 ULg)
Peer Reviewed
See detailRéunion scientifique de la Société Belge de Neurochirurgie
Martin, Didier ULg

Conference (2008, March 08)

Detailed reference viewed: 21 (2 ULg)
See detailLa trépanation : aspects historiques, techniques et éthiques
Martin, Didier ULg

Scientific conference (2008, January 23)

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailAbsence d'hypogonadisme chez un patient masculin avec prolactinome géant : un paradoxe clinique
Tamagno, Gianluca; Daly, Adrian ULg; Deprez, Manuel ULg et al

in Annales d'Endocrinologie (2008), 69(1), 47-52

Background Impotence and decreased libido are the cardinal features of prolactinomas in males. We describe the unusual clinical, pathological and biochemical features in a male patient with a giant ... [more ▼]

Background Impotence and decreased libido are the cardinal features of prolactinomas in males. We describe the unusual clinical, pathological and biochemical features in a male patient with a giant prolactinoma and normal gonadal function. Case Report A 57 year-old man presented with visual symptoms related to a 30 × 25 × 60 mm tumor of the sella and skull base. Biopsy revealed a pituitary adenoma and subsequent hormone profiles demonstrated grossly elevated serum prolactin (131,412 ng/ml), LH at the upper limit of normal and normal testosterone. The patient had no symptoms of decreased libido or impotence related to this giant prolactinoma. Immunohistochemistry revealed a tumor that was positive for prolactin, alpha-subunit and LH. Cabergoline greatly reduced prolactin levels but these remained above normal. LH, testosterone and alpha-subunit levels were decreased in parallel. Loss of libido and impotence became apparent when testosterone fell below normal, a situation that resolved with further cabergoline treatment and prolactin inhibition and testosterone therapy. Conclusions Sexual dysfunction is a hallmark of prolactinomas in males. Tumors that co-secrete prolactin and LH are extremely rare and this is the first such case reported in an adult male. In this case, normal testosterone was maintained by intact LH levels even in the face of the highest prolactin level reported to date. [less ▲]

Detailed reference viewed: 158 (8 ULg)